SCHEMBL2634210

SCHEMBL2634210

NC(=O)c1cc(C(F)(F)F)cnc1Cl

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.52
ALDH1A1 P00352 4/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 2/20 0.49
PLAU P00749 1/20 0.47
RAB9A P51151 2/20 0.45
HTT P42858 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 1/20 0.43
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SORT1 Q99523 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30056948 1.00 CASP1 (0.52) CASP1ALDH1A1GAAKMT2APLAU
Isophthalic Acid SCHEMBL29841704 0.86 MRGPRX4 (0.52) CASP1GAAKMT2AMAPTGLA
SCHEMBL2634725 0.84 ALDH1A1 (0.44) ALDH1A1GAAKMT2APLAUMAPT
SCHEMBL1585179 0.84 SORT1 (0.53) ALDH1A1GAAKMT2APLAUMEN1
SCHEMBL31344085 0.84 ALDH1A1 (0.44) ALDH1A1GAAKMT2APLAUMAPT
SCHEMBL29799010 0.84 SORT1 (0.53) ALDH1A1GAAKMT2APLAUMEN1
SCHEMBL16666657 0.81 KMT2A (0.50) CASP1ALDH1A1GAAKMT2APLAU
SCHEMBL15862919 0.79 KMT2A (0.49) CASP1ALDH1A1GAAKMT2APLAU
SCHEMBL9900680 0.79 MAPK1 (0.52) ALDH1A1GAAKMT2ACYP1A2CYP2C19
SCHEMBL24684142 0.78 NFKB1 (0.51) RAB9AMAPTSMN1; SMN2SORT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084064-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-13 US disclosed
US-12195445-B2 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2025-01-14 US disclosed
CN-113272293-B 2-Amino-N-heteroaryl-nicotinamide as NAV1.8 inhibitor 默沙东有限责任公司 2024-06-14 CN disclosed
US-20240166664-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-05-23 US disclosed
EP-4289845-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2023-12-13 EP disclosed
EP-4289845-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2023-12-13 EP disclosed
US-20230338429-A1 COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS UNIVERSITE DE MONTREAL (CA) 2023-10-26 US disclosed
CN-116724044-A Tri-heterocyclic compound, preparation method and application thereof 上海湃隆生物科技有限公司 2023-09-08 CN disclosed
US-11696928-B2 Compounds and use thereof in the expansion of stem cells and/or progenitor cells UNIVERSITE DE MONTREAL (CA) 2023-07-11 US disclosed
US-20230180754-A1 HETEROCYCLIC COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS BASF SE (DE) 2023-06-15 US disclosed
WO-2017133667-A1 PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 WO disclosed
EP-2580208-B1 CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA NV (BE) 2015-05-06 EP disclosed
EP-2580208-B1 CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA NV (BE) 2015-05-06 EP disclosed
US-8436023-B2 Cyclohexyl-azetidinyl antagonists of CCR2 JANSSEN PHARMACEUTICA N.V. (BE) 2013-05-07 US disclosed
US-8436023-B2 Cyclohexyl-azetidinyl antagonists of CCR2 JANSSEN PHARMACEUTICA N.V. (BE) 2013-05-07 US disclosed
EP-2580208-A1 CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 Janssen Pharmaceutica, N.V. (BE) 2013-04-17 EP disclosed
CN-102933575-A Yclohexyl-azetidinyl antagonists of ccr2 JANSSEN PHARMACEUTICA NV 2013-02-13 CN disclosed
WO-2011156554-A1 CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA NV (BE) 2011-12-15 WO disclosed
US-20110306592-A1 CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA N.V. (BE) 2011-12-15 US disclosed
WO-2011156554-A1 CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA NV (BE) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195445-B2 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors SCN8A, SCN2A, SCN1A CASP1 1936/4885ALDH1A1 1048/4885GAA 2702/4885
US-20250084064-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS SCN8A, SCN2A, SCN1A CASP1 1936/4885ALDH1A1 1048/4885GAA 2702/4885
US-20230180754-A1 HETEROCYCLIC COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS DDT, ACHE, CYCS CASP1 287/4885ALDH1A1 1384/4885GAA 803/4885
US-20110306592-A1 CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 CCR2, CCR1, CCR5 CASP1 3414/4885ALDH1A1 544/4885GAA 2735/4885
US-11696928-B2 Compounds and use thereof in the expansion of stem cells and/or progenitor cells MCL1, CD47, BMI1 CASP1 1455/4885ALDH1A1 35/4885GAA 428/4885
US-20230338429-A1 COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS MCL1, CD47, BMI1 CASP1 1455/4885ALDH1A1 35/4885GAA 428/4885
US-20240166664-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 CASP1 2969/4885ALDH1A1 1500/4885GAA 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.